No Biopsy Required For MRI-Detected BI-RADS 2 Lesions
Breast lesions detected by MRI and classified as BI-RADS 2 were shown to not be malignant, and therefore do not need biopsy.
Breast biopsies are unnecessary for breast lesions found by breast MRI and characterized as BI-RADS 2, according to a study published in the journal Clinical Radiology.
Researchers from Austria performed a retrospective single-center study to assess the frequency of malignancies in lesions characterized as benign on breast MRI.
A total of 1,265 patients, mean age 50, were included in the study. All had undergone dynamic contrast-enhanced MRI (1.5 T) of the breast during a six-year period.
The researchers examined the MRI characteristics and frequency of malignancy in 192 of the patients found to have breast lesions classified as BI-RADS 2.
The lesions were either histopathologically verified or subjected to both clinical and imaging follow-up of at least two years (range: two to nine years).
The results showed that no lesions that were classified as BI-RADS 2 were found to be malignant. “Histopathology was available in 67 (34.9%) lesions and revealed benign findings exclusively,” the authors wrote. “The remaining 125 (65.1%) lesions did not exhibit changes during the follow-up period and were, therefore, considered negative for malignancy.”
The researchers concluded that breast biopsies are unnecessary for breast lesions classified as BI-RADS 2, due to the absence of malignancies.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
